Resumen

LOSADA BUCHILLON, Rafael et al. Cardiotoxicity in patients with acute promyelocytic leukemia treated with doses of anthracyclines. Rev Cubana Hematol Inmunol Hemoter [online]. 2003, vol.19, n.2-3, pp. 0-0. ISSN 1561-2996.

Cardiotoxicity in patients with acute promyelocytic leukemia treated with doses of anthracyclines 18 patients with history of acute promyelocytic leukemia and treatment with anthracyclines were studied by echocardiography The fraction of ejection and that of shortening were used as indicators of the systolic function, whereas the ejection/shortening relation and the times of deceleration and of isovolumetric relaxation were utilized for the diastolic function. According to the time elapsed from the last dose of anthracyclines to the moment of the study, the patients were divided into 2 groups (group 1 with 12 or less months and group 2 with 12 or more months) to determine chronic and late cardiotoxicity, respectively. Average age in both groups was 31 years old. The accumulative doses of anthracyclines (ADA) expressed in milligrams per square meter of body surface (mg/m2) were 593.42 in group 1 and 497.27 in group 2. In group 1, 2 patients (28.5 %) presented alterations of the ventricular function as a reflex of chronic cardiotoxicity. In group 2, 2.5 patients (45.4 %) showed alterations of that function as a reflex of late cardiotoxicity. Of these 7 patients, 6 had received ADA over 400 mg/m2 . Of the 11 patients that did no have it, 10 had also received ADA over 400 mg/m2

Palabras clave : LEUKEMIA, MYCLOCYTIC, ACUTE [drug therapy]; ANTHRACYCLINES [therapeutic use]; ANTHRACYCLINES [toxicity]; MYOCARDIAL DISEASES.